Safety evaluation of soybean protein isolate oxidized by a hydroxyl radical-generating system

Characterization of soy protein isolate/Flammulina velutipes polysaccharide hydrogel and its immunostimulatory effects on RAW264.7 cells

Soy protein isolate (SPI) is a nutritional commercial product, while the poor solubility and gelling restricts its applications for functional foods. To surmount the challenge presented by this poor solubility, the gelling polysaccharide shows potential in ameliorating SPI. In this study, SPI/Flammulina velutipes polysaccharide (FVP) hydrogels were prepared under four mixing ratios (32:1, 20:1,15:1 and 10:1, w/w) at both pH6.5 and pH3.5, respectively. The stability of hydrogels and its immunostimulatory impact on RAW264.7 cells were assessed. Initial results revealed that water holding capacity increased when increasing the mixing ratios, likely to be the results of enhanced electrostatic interaction between SPI and FVP. The addition of FVP contributed to the improved swelling ratio and lowered the degradation ratio. Such structure feature was shown to be favorable for hydrogels to culture cells. More importantly, SPI/FVP hydrogels demonstrated no cytotoxic effect on cell metabolic activity. The culture of SPI/FVP hydrogels enhanced the immunostimulatory capacity in RAW264.7 cells by increasing phagocytosis and inducing the production of pro-inflammatory cytokines. The performances of the hydrogels made at pH3.5 were superior to those prepared at pH6.5. Our results suggested SPI/FVP hydrogels may provide application potential for the development of functional foods.

Lack of mutagenicity, genotoxicity and developmental toxicity in safety assessment tests of Lactobacillus mali APS1

Lactobacillus (L.) mali APS1 isolated from sugary kefir grains has been proven to affect energy and glucose homeostasis. However, without proper safety assessment it cannot be recommended as probiotics for human consumption. For genotoxicity, the Ames test showed no mutagenic effect of L. mali APS1 in the presence or absence of S9 mix metabolic activation. In-vitro mammalian chromosomal aberration test showed that the number of Chinese hamster ovary cells with abnormal chromosomes was <5% after L. mali APS1 treatment. Moreover, L. mali APS1 showed no risk of genotoxicity potential compared to the control. L. mali APS1 administration did not cause significant (p>0.05) changes in body weight, the number of reticulocytes, or in the occurrence percentage of micronucleus in Imprinting Control Region (ICR) mice. Based on the absence of maternal or fetal effects at any dosage level investigated, the teratogenicity could be defined as greater than 1,670 mg/kg b.w./day for maternal general toxicity and fetal development when L. mali APS1 was orally administered by gavage to pregnant SD rats during gestation days 6 to 15.

Soybean isoflavones ameliorate ischemic cardiomyopathy by activating Nrf2-mediated antioxidant responses

Ischemic cardiomyopathy (IC) is the major cause of heart failure. Conventional medicine has been proved ineffective with adverse effects. Soybean presents exciting adjunctive therapies and shows protective benefits for IC. However, the molecular mechanisms remain unclear. Isoflavones are the main bioactive components of soybean and may be protective against heart disease. Isoflavones were extracted by using an acidic-ethanol method and analyzed by HPLC. All patients with ischemic stroke were randomly and evenly assigned to two groups: the isoflavone group (80 mg day-1, n = 100) and control group (80 mg day-1 placebo, n = 100), and the whole period of the experiment was 24 weeks. The effects of soybean isoflavone on brachial flow-mediated dilatation (FMD) were measured. HPLC fractionation shows that isoflavone extracts are mainly composed of 55% genistein, 23% daidzein, and 14% glycitein. Isoflavone therapy reduced more levels of triglyceride and LDL-c in females than in males. FMD was higher in the isoflavone group than in the control group after 24-week therapy (treatment effect 2.0%, 95% CI 0.18-3.0, P = 0.01). The baseline differences were adjusted in FMD and the isoflavone therapies were closely associated with the reduction of FMD impairment at 24 weeks (odds ratio 0.30, 95% CI 0.14-0.85, P = 0.01). The effects of isoflavone on brachial FMD were negatively associated with base FMD (r = -0.65, P < 0.01). Furthermore, isoflavone therapy caused a significant increase in the levels of erythroid-derived 2-like 2 (Nrf2), superoxide dismutase (SOD) and a significant decrease in serum levels of C-reactive protein, 8-isoprostane, malondialdehyde, interleukin-6 and tumor necrosis factor alpha. In contrast, the isoflavones had no effects on the levels of oxidation-related molecules when Nrf2 was silenced. These results suggest that soybean isoflavones ameliorate IC patients by improving their antioxidant capacities via the upregulation of Nrf2.